Informed investors are not expecting it because of the reason you cited. Nonetheless, eight months without news catalysts inevitably results in a decay in the stock price. If the data is convincingly strong, I would much preferred that Missling move forward aggressively with filing an NDA, which he should have been comfortably able to do right out we get the EXCELLENCE top line results. When compelling data is involved, I don't see the point of waiting for an indefinite period for peer review. Time is money.
"I'm fully expecting to see a journal that incorporates a wealth of information, covering several indications, raising the expectations of a generally effective drug for most all CNS disorders."
That sounds good but multiple years of trials would still be required in those disorders. I say let the bird already in your hand fly and forego peer review.
Agree w/this thinking. Also expect that, as the field of AI information on CNS root cause blossoms, S1R will reveal as a key factor. AVXL should be well established as a leader in what then follows WW.
There’s a reason Missling said it would likely be published in a journal. It gives him an infinite amount of time to kick the cab knowing people would say it’s embargoed